In Re: Application of Rosa Carolina Germano Dos Santos

CourtDistrict Court, D. New Jersey
DecidedMarch 8, 2024
Docket2:22-cv-01567
StatusUnknown

This text of In Re: Application of Rosa Carolina Germano Dos Santos (In Re: Application of Rosa Carolina Germano Dos Santos) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re: Application of Rosa Carolina Germano Dos Santos, (D.N.J. 2024).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN THE MATTER OF THE APPLICATION OF ROSA CAROLINA GERMANO DOS SANTOS Civil Action No. 22-01567 ET AL. FOR AN ORDER UNDER 28 U.S.C. § 1782 TO TAKE DISCOVERY FROM BAYER OPINION AND ORDER HEALTHCARE PHARMACEUTICALS INC. AND BAYER HEALTHCARE, LLC SEMPER, District Judge. The current matter comes before the Court on Respondents’ Appeal from Magistrate Judge Allen’s August 4, 2023, Order (ECF 36, “August Order”) denying Respondents’ Motion to Quash Petitioners’ Subpoenas. (ECF 37, “App.”) Petitioners opposed the appeal. (ECF 38, “Opp.”) Respondents filed a brief in reply. (ECF 39, “Reply.”) The Court has decided this appeal pursuant to Federal Rule of Civil Procedure 72(a) and Local Civil Rule 72.1(c), and upon the submissions of the parties, without oral argument, pursuant to Federal Rule of Civil Procedure 78. For the reasons stated below, Respondents’ Appeal is DENIED and the Honorable Jessica S. Allen, U.S.M.J.’s August Order is AFFIRMED. I. BACKGROUND Petitioners consist of 387 women who have allegedly suffered injuries from Essure permanent birth control implants (“Essure”). (ECF 1-1 ¶¶ 39-40.) Petitioners specifically allege that between approximately June 2013 and December 2018, Essure was marketed as a Bayer product in Brazil. (Id. 1-1 ¶¶ 1-7.) According to Petitioners, Essure was developed in 1998 by Conceptus, Inc., a United States based company (Id. at ¶ 1.) Bayer AG, Respondents’ German parent company, is alleged to have acquired Conceptus in June 2013. (Id. at ¶ 5.) Petitioners further allege that once acquired, Conceptus became a wholly owned subsidiary of Respondent Bayer LLC, a United States based company; thereafter, Conceptus was renamed Bayer Essure Inc. and subsequently transferred “substantially all” of its operating tangible assets and liabilities to Bayer Healthcare, LLC. (Id. at ¶ 6.) Further, after the acquisition, “Bayer Healthcare, LLC became the

entity directly responsible for the manufacturing, assembly and research and development of Essure contraceptive coils,” while Bayer Healthcare Pharmaceuticals assumed other functions including marketing, sales, and distribution in the United States. (Id. at ¶¶ 8-9.) In July 2021, Petitioners sent a demand letter to Bayer AG threatening a products liability lawsuit in the Regional Court of Cologne, Germany. (ECF 1-2 Ex. 2.) Bayer AG rejected Petitioners’ demand. (Id.) However, Petitioners did not immediately sue. Instead, on March 21, 2022, they filed an ex parte application in this Court, pursuant to 28 U.S.C. § 1782, seeking to serve Respondents with discovery subpoenas for documents and deposition testimony in aid of their anticipated German lawsuit against Bayer AG. (ECF 1.) Claiming that Respondents, which have their principal places of business in this District, possess useful information for their

anticipated lawsuit against Bayer AG, Petitioners sought to serve the subpoenas on Respondents. To that end, Petitioners submitted four proposed subpoenas as part of their Section 1782 application: two document subpoenas with thirty-nine requests for production of documents and two deposition subpoenas with twenty-eight topics. (ECF 1-3 Exs. 15-18 at 237-97.) Petitioners also submitted a sworn declaration from Spangenberg, detailing pre-litigation efforts and investigation, legal theories (which include a manufacturing defect, failure to warn, and failure to prevent dangerous misconduct), and critical factual issues for trial. (ECF 1-2 ¶¶ 7-11.) Based on Judge Allen’s review of the ex parte submission and supporting declarations, on July 22, 2022, Judge Allen issued an Order, granting Petitioners’ application without prejudice to Respondents’ right to move to quash or modify the subpoenas. (ECF 3.) Petitioners served their proposed subpoenas on Respondents. On October 18, 2022, after an unsuccessful meet and confer, Respondents requested leave to file a motion to quash the subpoenas. (ECF 4.) Following a Telephonic Status Conference on

November 3, 2022, Judge Allen granted Respondents leave. Respondents filed motions to quash and strike. Judge Allen’s August Order denied Respondents motion to quash and granted Respondents motion to strike. (ECF 36.) In her opinion, Judge Allen found that Petitioners satisfied the Section 1782 statutory requirements and found that the four discretionary Intel factors weighed in favor of granting the Section 1782 application. (ECF 35, Opinion.) Respondents filed an appeal of Judge Allen’s August Order with respect to the denied motion to quash the subpoenas. (ECF 37, App.) Petitioners filed an opposition brief responding to Respondents’ appeal. (ECF 38, Opp.) Respondents filed a reply brief. (ECF 39, Reply.) II. LEGAL STANDARD In a district judge’s review of a magistrate judge’s decision, Federal Rule of Civil

Procedure 72(a) states: “[t]he district judge. . . must consider timely objections and modify or set aside any part of the order that is clearly erroneous or is contrary to law.” Similarly, the Local Rules for this district provide that “[a]ny party may appeal from a [m]agistrate [j]udge’s determination of a non-dispositive matter within 14 days” and the district court “shall consider the appeal and/or cross-appeal and set aside any portion of the [m]agistrate [j]udge’s order found to be clearly erroneous or contrary to law.” Local Civ. R. 72.1(c)(1)(A). Further, “[a] discovery order is generally considered to be non-dispositive.” Williams v. American Cyanamid, 164 F.R.D. 615, 617 (D.N.J. 1996). A district judge may reverse a magistrate judge’s order if the order is shown to be “clearly erroneous or contrary to law” on the record before the magistrate judge. 28 U.S.C. § 636(b)(1)(A) (“A judge of the court may reconsider any pretrial matter [properly referred to the magistrate judge] where it has been shown that the magistrate judge’s order is clearly erroneous or contrary to law.”); Fed. R. Civ. P. 72(a); Local Civ. R. 72.1(c)(1)(A); Haines v. Liggett Grp., Inc., 975 F.2d 81, 93 (3d Cir. 1992) (describing the district

court as having a “clearly erroneous review function,” permitted only to review the record that was before the magistrate judge). The burden of showing a ruling is clearly erroneous or contrary to law rests with the party filing the appeal. Marks v. Struble, 347 F. Supp. 2d 136, 149 (D.N.J. 2004). A district court “will determine that a finding is clearly erroneous ‘when although there is evidence to support it, the reviewing court on the entire evidence is left with the definite and firm conviction that a mistake has been committed.’” Dome Petroleum Ltd. v. Emp’rs Mut. Liab. Ins. Co., 131 F.R.D. 63, 65 (D.N.J. 1990) (quoting United States v. United States Gypsum Co., 333 U.S. 364, 395 (1948)). However, “[w]here there are two permissible views of the evidence, the factfinder’s choice between them cannot be clearly erroneous.” United States v. Waterman, 755 F.3d 171, 174 (3d Cir. 2014) (quoting Anderson v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. United States Gypsum Co.
333 U.S. 364 (Supreme Court, 1948)
Anderson v. City of Bessemer City
470 U.S. 564 (Supreme Court, 1985)
Intel Corp. v. Advanced Micro Devices, Inc.
542 U.S. 241 (Supreme Court, 2004)
Heraeus Kulzer GmbH v. Esschem, Inc.
390 F. App'x 88 (Third Circuit, 2010)
No. 97-5047
146 F.3d 188 (Third Circuit, 1998)
Bayer AG v. Betachem, Inc.
173 F.3d 188 (First Circuit, 1999)
Gunter v. Ridgewood Energy Corp.
32 F. Supp. 2d 162 (D. New Jersey, 1998)
Kounelis v. Sherrer
529 F. Supp. 2d 503 (D. New Jersey, 2008)
Marks v. Struble
347 F. Supp. 2d 136 (D. New Jersey, 2004)
United States v. Robert Waterman
755 F.3d 171 (Third Circuit, 2014)
In Re The Application of Kate v.
646 F. App'x 263 (Third Circuit, 2016)
Mees v. Buiter
793 F.3d 291 (Second Circuit, 2015)
Williams v. American Cyanamid
164 F.R.D. 615 (D. New Jersey, 1996)
Kresefky v. Panasonic Communications & Systems Co.
169 F.R.D. 54 (D. New Jersey, 1996)
Cooper Hospital/University Medical Center v. Sullivan
183 F.R.D. 119 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
In Re: Application of Rosa Carolina Germano Dos Santos, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-application-of-rosa-carolina-germano-dos-santos-njd-2024.